For research and educational purposes only. Not intended for human consumption.
IGF-1 LR3
Limited Research- •WADA prohibited substance status maintained
- •PI3K/Akt/mTOR pathway mechanism research
- •IGFBP binding reduction studies
Modified Growth Factor Analog | Research Chemical Only
Overview
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic 83-amino acid analog of human insulin-like growth factor-1 that has never been approved for human use in any country. Despite approximately 3x greater potency than native IGF-1 with a 20-30 hour half-life due to reduced IGF-binding protein interaction, no human clinical trials have ever been conducted. WADA prohibited. Banned by WADA
Key Benefits
Approximately 3x more potent than native IGF-1 with 20-30 hour half-life due to reduced IGFBP binding. Promotes both muscle hypertrophy and hyperplasia in animal models.
Mechanism of Action
Full IGF-1 receptor agonist with reduced IGF-binding protein interaction. N-terminal extension and R3 substitution prevent sequestration, maintaining free circulating levels. Activates PI3K/Akt/mTOR and MAPK/ERK pathways.
Molecular Information
Pharmacokinetics
Research Indications
Muscle Hypertrophy
Animal studies show 15-20% lean mass gains in 4 weeks through satellite cell activation and protein synthesis enhancement. No human data exists.
Anti-Catabolic Effects
Preserves lean mass in cachexia models through ubiquitin-proteasome inhibition.
Hyperplasia Induction
Unique ability to create new muscle fibers via satellite cell differentiation, not just enlarging existing fibers.
Research Protocols
Disclaimer: CRITICAL: IGF-1 LR3 has never been approved for human use. No human clinical trials exist. All use represents uncontrolled experimentation with significant risks.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Research Beginner Protocol | 20-30mcg | Once daily, post-workout | Subcutaneous |
| Intermediate Research Use | 40-60mcg | Once daily, post-workout or morning | Subcutaneous or IM |
| Advanced Research Protocol | 80-100mcg | Once daily or split AM/PM | Subcutaneous or site-specific IM |
| Women's Research Protocol | 10-20mcg | Once daily | Subcutaneous only |
Timing: Post-workout window critical for safety and efficacy. IGF-1 receptors most sensitive when muscles depleted. Must consume carbohydrates immediately to prevent dangerous hypoglycemia lasting up to 30 hours.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Equilibrate vial to room temperature (15-30 min)
Sanitize rubber stopper with alcohol
Calculate concentration (e.g., 1mg in 2mL = 500mcg/mL)
Use 0.6% acetic acid - BAC water causes rapid degradation within 2-3 days
Inject slowly along vial wall, not directly on powder
Gently swirl - never shake vigorously
Allow to dissolve completely (2-5 min)
Store immediately at 2-8°C protected from light
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Research Chemical Status
Never approved for human use. Zero human clinical trials. All use represents uncontrolled experimentation.
Severe Hypoglycemia Risk
Can cause life-threatening low blood sugar lasting 20-30 hours. Multiple animal deaths documented in studies.
Cancer Proliferation Concern
UK Biobank study links elevated IGF-1 to multiple cancers. May accelerate growth of existing tumors.
Purity Testing Essential
Require HPLC >95% and mass spectrometry confirmation. Black market samples often degraded.
Species-Specific Responses
Works in rats, fails in guinea pigs, inhibits growth in pigs. Human response entirely unknown.
What to Expect
- •Week 1-2: Increased pump, fullness, possible hypoglycemia episodes if carbs inadequate
- •Week 2-4: Enhanced recovery, strength gains, visible muscle fullness, possible water retention
- •Week 4-6: Maximum effects but approaching receptor desensitization. Joint stiffness common.
- •Post-cycle: Gradual loss of pumps over 1-2 weeks. Strength/size gains may persist if training maintained.
Side Effects & Safety
Side Effects
- •CRITICAL: Consume 30-60g fast carbohydrates immediately after injection
- •Never inject before sleep - overnight hypoglycemia risk
- •Monitor blood glucose regularly, especially first week
- •Contraindicated with any cancer history or undiagnosed growths
- •May cause organ hypertrophy (heart, intestines) with prolonged use
- •WADA prohibited - will cause failed drug test in athletes
When to Stop
- •Signs of hypoglycemia
- •Any signs of abnormal growth
- •Chest pain or heart issues
- •Significant joint pain
- •As directed by healthcare provider
References
3 StudiesRat Muscle Hypertrophy Study (Florini et al.)
Sprague-Dawley Rats | 2.5mg/kg/day | 4 weeks | 15-20% lean mass increase
Demonstrated 2.5x greater anabolic response compared to native IGF-1. Satellite cell activation and protein synthesis increased by 50%.
Fetal Sheep Metabolic Study
Fetal Sheep | Various doses | Study halted early | Study halted - 4 animal deaths
Acute infusion suppressed insulin secretion by 66%. Chronic infusion caused 4 animal deaths from hypoglycemia and hypoxemia.
Pig Growth Inhibition Study
Domestic Pigs | 180μg/kg/day | 4 days | Paradoxical growth reduction
Contrary to expectations, decreased average daily gain and food intake. Growth hormone dropped 23%.
Quick Start Guide
Research Disclaimer
IGF-1 LR3 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving IGF-1 LR3 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of IGF-1 LR3 for any purpose. Consult qualified professionals for any research applications.